Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategy
Rescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives

TORONTO, April 28, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, applauds the announcement by the U.S. Department of Justice and U.S. Drug Enforcement Administration to reschedule certain cannabinoid-based products from Schedule I to Schedule III under the U.S. federal Controlled Substances Act, in furtherance of President Trumps Executive Order of December 18, 2025. The Company applauds this development as a meaningful step towards advancing scientific research, improving regulatory clarity, and expanding patient access. The Company is pleased to provide an update of its scientific, R&D, clinical development, and medical affairs initiatives and programs, while continuing to evaluate strategic opportunities in the U.S.

Management Commentary

“We are encouraged by actions and announcements of the current U.S. Administration toward a more evidence-based and pragmatic framework for cannabinoid-based products” said Aras Azadian, Chief Executive Officer of Avicanna. “This milestone reinforces the importance of rigorous scientific development and aligns closely with Avicanna’s long-standing strategy of advancing pharmaceutical-grade cannabinoid products alongside standardized medical cannabis platforms. As the regulatory landscape evolves, we believe Avicanna is well positioned to leverage its intellectual property portfolio, pipeline, and vertically integrated capabilities to support our strategic roadmap toward participation in the U.S.”

Scientific and Medical Highlights (2026 YTD)

Clinical Development:

Avicanna continues to advance a robust clinical development strategy supported by both real-world evidence and randomized controlled trials.

• An ongoing real-world evidence study evaluating physician-authorized medical cannabis has published findings demonstrating improvements in pain-related outcomes, mental health measures, and quality of life (Canadian Journal of Pain).
• Initiation of a Phase I randomized, double-blind, placebo-controlled dose-finding study in collaboration with the University of Calgary’s Cumming School of Medicine, evaluating dose-dependent effects of oral THC on anxiety and stress using Avicanna’s proprietary capsule formulations.
• Progress in a previously announced Phase II randomized controlled trial evaluating cannabinoid-based formulations for arthritic pain, initial patient enrollment commenced in early 2026.

Research & Development

The Company continues to make meaningful progress across its proprietary R&D pipeline. Continued advancement, commercialization, and optimization of Avicanna’s proprietary delivery technologies, including the QUIX™ rapid onset nanotechnology platform, supporting both pharmaceutical and medical cannabis applications.

Medical Affairs and Scientific Engagement

Avicanna continues to expand engagement with healthcare professionals through targeted education and collaboration, including the growth of Avicenna Academy, which supports evidence-based clinical decision-making, alongside the MyMedi.ca platform, which enhances patient access through pharmacist-led support programs, reimbursement initiatives, and specialized care pathways. The Company recently announced its 6^th Annual Clinical Symposium on Cannabinoid Therapeutics, a leading forum for clinical dialogue, patient outcomes, and emerging therapeutic applications, to be held in an expanded two-day format, both in-person and virtually, bringing together clinicians, researchers, and key stakeholders.

Strategic Outlook

The evolving U.S. regulatory framework represents a significant milestone in the integration of cannabinoid-based therapeutics within a pharmaceutical framework. Avicanna will continue to monitor regulatory developments and assess pathways to leverage its scientific platform, proprietary formulations, and clinical data in support of future U.S. market entry, with a focus on:

• Pharmaceutical development and FDA-aligned pathways including clinical development in the US
• Evidence-driven and Federal or State level medical cannabis models
• Strategic partnerships and licensing opportunities

About Avicanna Inc

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
  
  
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
  
  
• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
  
  
• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc. 

Stay Connected

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com. 

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general and special meeting of shareholders will be held virtually on Thursday, May 7, 2026 at 11:30 AM (Toronto Time).   

Materials for the meeting will be available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on its website at https://ir.avicanna.com/ir/annual-general-meeting/, on or about April 16, 2026, with Proxy Cut-Off May 5, 2026 at 11:30 AM (Toronto Time).  

About Avicanna: 

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. 

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 

• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 

• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 

• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. 

SOURCE Avicanna Inc.  

Stay Connected  

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.  

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. 

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products will host its 6th annual clinical symposium on Cannabinoid-based Therapeutics – “From Emerging Evidence to Clinical Practice” on June 11-12, 2026 at the MaRS Discovery District, Toronto.  

 

Researchers, industry professionals, and healthcare practitioners from across Canada and internationally will convene for an expanded two-day program focused on current evidence and clinical considerations in cannabinoid therapeutics. Over successive years, the symposium has brought together various physicians, researchers, pharmacists, and healthcare professionals from academic and clinical settings to support clinical dialogue and research exchange related to patient care. 

The 2026 symposium will feature an expanded agenda including new research findings, case-based clinical discussions, and multidisciplinary panels focused on prescribing practices, treatment planning, and patient management. The program reflects ongoing interest in the integration of cannabinoid-based therapies into clinical practice, alongside recognition of existing evidence gaps and variability in clinical guidance. Speakers will include clinicians and researchers representing disciplines such as primary care, pain management, neurology and psychiatry across various therapeutic needs and patient populations. 

“This symposium provides clinicians and researchers an opportunity to review emerging evidence, share real-world clinical experience, and examine the role of cannabinoid-based therapies in patient care” said Karolina Urban, Executive Vice President of Medical Affairs at Avicanna. “This year’s program places a deliberate focus on areas that are often underrepresented, including women’s health, evidence-informed care for veterans, and the translation of research into practical clinical decision making.”  

In addition to live sessions, this event will be recorded and made available through the Avicenna Academy, our growing library of clinical resources, recorded lectures, and educational materials designed to support. 

Healthcare professionals interested in attending or showcasing their research at the symposium are invited to register online or submit posters for consideration by the organizing committee. 

 

 

Speaker	Topic
Dr. James MacKillop, PhD, CPsych, FCAHS McMaster University, St. Joseph’s Healthcare Hamilton	State of the evidence for medical cannabis in Canada
Dr. Daniel Bear, PhD Humber Polytechnic	Symptoms & Science: What we know about cannabinoids, where evidence is lacking, and why absence of evidence isn’t evidence of absence.
Dr. Evan Lewis, MD, FRCPC University of Toronto, Pediatrics	Clinical Workshop: Prescribing medical cannabis — practical approaches to initiation, titration, and patient management
Dr. Matthew Hill, PhD University of Calgary	Neurobiology, hyperarousal, and clinical considerations
Dr. Zachary Walsh, PhD, RPsych University of British Columbia	Clinical evidence for harm reduction and substitution
TBD – Veterans & Veteran Support Groups	Veteran and patient perspectives — clinical needs, outcomes, and barriers to care
Dr. Hance Clarke, MD, PhD, FRCPC Toronto General Hospital, University Health Network	Evidence from RWE study and next steps in pain-related medical cannabis prescription.
Dr. Elizabeth Thompson, PhD, MSc University of Saskatchewan	Brain injury, cannabinoids, and the endocannabinoid system
Michael Koehn, MACP, RCC, CHPC Cannsolve	The Maverick Medical Cannabis Project: Insights and implementation of a novel intervention for the overdose crisis.
Dr. Dilshaan Panjwani, MD BC Cancer	Medical Cannabis Extracts for Cancer-Related Symptoms: Results of an innovative n-of-1 clinical trial
Erin Mignault, NP, MSc June Health, KixCare, Care2Talk Health	Clinical Workshop on Women’s Health: Menopause — pathophysiology and the role of cannabinoid-based therapies
Dr. Luiza Marouelli, MD, OB-GYN Sante Cannabis	Cannabinoids in Gynecologic Care: Real-World Applications and Clinical Experience

 

About the Symposium 

The Annual Clinical Symposium on Cannabinoid Therapeutics is a national scientific forum dedicated to advancing evidence-based education, research, and clinical practice in cannabinoid medicine. The symposium brings together healthcare professionals across disciplines to examine emerging data, discuss clinical applications, and address limitations in current evidence related to cannabinoid-based therapies.  

About Avicanna: 

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. 

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 

• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 

• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 

• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. 

SOURCE Avicanna Inc.  

Stay Connected  

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.  

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. 

TORONTO, April 06, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces effective Thursday April 1, 2026 the resignation of John McVicar and pleased to announce the appointment of Mr. Ozgur Kilic to the Board of Directors of the Company.

Mr. Kilic is an experienced global business executive and Chief Executive Officer with a background as a strategic Chief Financial Officer and Chief Operating Officer with more than 20 years of experience at various global public companies and private equity backed pharma companies across the US, UK, Italy, and Switzerland. Mr. Kilic is a graduate of Koc University (BA, Business Administration; BA, History) and Stuttgart Institute of Management and Technology (MBA, Finance & Investment) and is qualified as Associate Chartered Management Accountant (ACMA) and Chartered Global Management Accountant (CGMA) by the Chartered Institute of Management Accountants.

“I am honored and excited to join the Board of Directors at Avicanna at such a pivotal time in the company’s evolution. Through the hard work, resilience, and dedication of its management team, the company is reaching a meaningful value inflection point, driven by a differentiated portfolio of existing products and a promising pharmaceutical pipeline focused on addressing significant unmet medical needs. I look forward to contributing to Avicanna’s continued growth, especially its plans to expands its presence in the United States and strengthens its international footprint, delivering innovative therapies that can improve patient outcomes worldwide.”

About Avicanna:
Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products.

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
  
• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
  
• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
  
• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
  
  

Stay Connected

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

TORONTO, April 1, 2026 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that its full year 2025 results, audited financial statements with management’s discussion and analysis have been filed. 

“Throughout the year, we strengthened our leadership in cannabinoid-based medicine by advancing our research and development programs, progressing clinical initiatives, and deepening engagement with the Canadian medical community. We delivered the strongest financial performance in our history, reflecting operational discipline, optimization, and efficiencies.  

“We also made targeted investments across our platforms to support commercial scalability, advanced product development, and enhanced the capabilities of the MyMedi.ca platform. These initiatives position Avicanna to scale efficiently, expand internationally, and unlock the full value of our business units and intellectual property globally.” stated Aras Azadian, CEO of Avicanna. 

Earnings call: Management will host an earnings call and corporate update on Tuesday April 7th at 8:00 a.m. Eastern time. Presenters will include Aras Azadian, CEO, Nick Hillborn, Interim CFO and Dr. Karolina Urban, EVP, Medical Affairs. To register, follow the link: https://zoom.us/webinar/register/WN_RJACfyrPSo6CpVfSzcx5SQ 

Financial Highlights: 

• Revenue and Gross Profit: Revenue totaled $6.6 million in Q4 2025 and $25.48 million for the year ended December 31, 2025, consistent with $6.6 million and $25.46 million, respectively, in the prior year. Gross margin expanded to 53% in 2025 from 51% in 2024, driving gross profit to $13.4 million, compared to $12.9 million in the prior year. Margin expansion reflects continued optimization of product mix and cost efficiencies. 

• Adjusted EBITDA: The Company generated positive adjusted EBITDA of $0.31 million in Q4 2025, compared to $(0.79) million in Q3 2025, reflecting improved operating leverage. For the year ended December 31, 2025, the Company achieved near break-even adjusted EBITDA with $(0.29) million, representing a 76% improvement compared to $(1.01) million in 2024. The year-over-year improvement was primarily attributable to higher gross margins and a 10% reduction in operating expenses. 

Highlights and Advancements During 2025: 

Canadian Commercial Advancements: During 2025 the Company further advanced its Canadian commercial platform across new SKUs, channels and listings. Additionally, the Company’s MyMedi.ca platform recovered from a modest Q1 performance of decreased sales, with three consecutive quarters of growth, combined with consistent increases in the proportion of sales attributed to Avicanna’s proprietary products. This resulted in 211,090 units of proprietary products sold during 2025, an increase of approximately 5% from 2024. At the end of the fourth quarter, the Company had 52 commercial SKUs and 174 commercial listings across medical and adult use channels, representing 27% growth in proprietary commercial SKUs and a 32% growth in total listings from Q4 2024.  

Initiation of Pilot Phase II Clinical Study for Osteoarthritis Pain with UHN: The multicenter, blinded, randomized placebo-controlled investigator-initiated study, will be led by Dr. Hance Clarke and conducted at University Health Network. The study will analyze the effectiveness of Avicanna’s proprietary oral cannabis extracts for osteoarthritic pain and is the Company’s first placebo controlled, blinded randomized multicenter trial “RCT”. The study is funded by a Canadian Institutes of Health Research (“CHIR”) grant and is sponsored by Avicanna, which is providing its proprietary CBD and THC capsules produced under Good Manufacturing Practices (“GMP”) for the trial.  

Promising Pre-clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform: The PwdRx technology was designed to address key formulation challenges associated with highly lipophilic cannabinoids, which often exhibit poor water solubility, low and variable bioavailability, and delayed onset of action. The technology demonstrated positive results in recent in-vitro study including 74% higher bioavailability (AUC), 63% faster peak plasma levels (TMAX) and a 134% higher peak plasma concentration (CMAX) when compared to an MCT oil formulation. The Company also filed a provisional patent application on the novel drug delivery platform which can be incorporated into products such as tablets, capsules, sachets and pouches. 

Scientific and Medical Affairs Collaboration with Aspeya Switzerland SA: The scientific and medical affairs collaboration with Aspeya Switzerland SA (formerly Vectura Fertin Pharma) a subsidiary of Philip Morris International, aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada. The scientific and medical affairs collaboration will prioritize engagement with the Canadian medical community, patients, patient advocacy groups, and insurers to gain insights into the challenges associated with accessing medical cannabis. The scientific and medical affairs collaboration will leverage Avicanna’s medical cannabis platform, including MyMedi.ca, with the aim of improving patient access and patient support. 

Symposium on Cannabinoid-based Medicine (June 2025): Held at the MaRS Discovery District in Toronto, Avicanna’s fifth symposium brought together leading key opinion leaders and healthcare professionals to explore advancements in cannabinoid-based research, medicine, and clinical adoption. The event’s attendees included healthcare practitioners and researchers, and featured discussions on emerging evidence and practical clinical applications of cannabinoid-based medicine. The program showcased insights from prominent clinicians, researchers, scientists, and industry experts representing a range of academic, clinical, and research institutions. 

First Commercial Exports of Premium and Organic Cannabis Flower: Santa Marta Goldan Hemp SAS (“SMGH”), the Company’s majority owned subsidiary, completed its first export of organic certified flower into Switzerland during Q3 2025 and its first commercial export of organic flower to Australia in Q1 2026. The accumulated exports represent the 22nd international market for SMGH and 24 market for Avicanna. These new commercial opportunities are the result of improvements to the SMGH infrastructure and expansion of the Aureus portfolio to meet the growing demand of medical cannabis flower in Europe and Australia. 

Avicanna LATAM SAS Launches re+PLAY™ CBD Wellness Brand Topicals with Harrington Wellness Brands in the United States: re+PLAY™ is a CBD wellness brand founded by NBA veteran Al Harrington that features Avicanna’s patented and proprietary CBD and CBG topical formulations. Initial product offerings include a 3% CBD localized cream and the 2% CBD and 1% CBG transdermal gel employing Avicanna’s patented deep tissue technology. The CBD and CBG used in the formulations are derived from USDA organic certified hemp cultivated in Avicanna’s subsidiary SMGH and manufactured by the Avicanna LATAM SAS team in Colombia.  

About Avicanna: 

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. 

• Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 

• Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 

• Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 

• Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. 

SOURCE Avicanna Inc.  

Stay Connected  

For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com.  

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.